Notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #43, ACCS #37, Joint ACMS-ACCS #35

This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes:

• Decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR, 42ZCZW and 42ZCZU. 
• reasons for that final decision
• date of effect of the decision.

Final decisions in relation to palmitoylethanolamide (PEA) and glycopyrronium

Note that the final decisions for palmitoylethanolamide (PEA) and glycopyrronium are not published in this notice. These decisions have been deferred to a later date while the information provided during the interim decision consultation period is further considered.

Final decision and reasons

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.

Contents

• Notice of final decisions to amend (or not amend) the current Poisons Standard
• Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #43, November 2023)
  • Astodrimer sodium
  • Bilastine
  • BPC-157
  • Methenamine
  • Naratriptan
  • Paracetamol
• Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #37, November 2023)
  • Animal blood products
  • Bile acids
• Final decisions on proposed amendments referred to the Advisory Committees on Medicines and Chemicals Scheduling in joint session (ACMS-ACCS #35, November 2023)
  • Adrenaline
  • Benzoic acid
  • Meloxicam
• Delegate-only decisions
  • Capromorelin
  • Prasterone
• Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
  • Abrocitinib
  • Bulevirtide
  • Clascoterone
  • Elranatamab
  • Etranacogene dezaparvovec
  • Etrasimod
  • Fezolinetant
  • Lebrikizumab
  • Lecanemab
  • Maribavir
  • Nelarabine
  • Relugolix
  • Tebentafusp
  • Zilucoplan